目的 :探讨血清铁蛋白 (SF)水平对有HBVC基因启动子 (BCP)变异的患者干扰素疗效的影响。方法 :采用错配PCR RFLP技术检测HBVC基因启动子 (BCP)变异 ,并检测其血清铁蛋白 (SF)水平。结果 :随着病情的加重SF水平升高 ,且当SF≥ 30 0ng/ml时 ,可明显降低干扰素的疗效 (P <0 0 5 ) ;发生BCP变异的病例 ,在干扰素治疗的过程中 ,SF水平升高的程度明显高于野生株组 (P <0 0 0 1)。结论 :提示SF升高与肝功能损伤有着密切关系 ,SF水平升高可降低干扰素治疗的有效率 ,且有变异的病例可促使SF水平升高。 Objective: To investigate the effect of serum ferritin (SF) on the efficacy of interferon in patients with variant of HBV C gene promoter (BCP). Methods: The mutation of HBVC gene promoter (BCP) was detected by mismatched PCR RFLP and the level of serum ferritin (SF) was detected. Results: The SF level increased with the severity of illness, and when SF≥30 0 ng / ml, the effect of interferon could be obviously reduced (P <0.05). In the cases of BCP mutation, , SF level was significantly higher than the wild-type group (P <0 0 0 1). Conclusion: It is suggested that there is a close relationship between the elevation of SF and liver injury. The increase of SF level can reduce the efficiency of interferon treatment, and the mutation cases can promote the increase of SF level.